Immunoadsorption in dilated cardiomyopathy patients

  • Stephan B. Felix
  • Alexander Staudt
Part of the Progress in Inflammation Research book series (PIR)


Abnormalities of the cellular and humoral immune system have been described in patients with dilated cardiomyopathy (DCM). Various circulating cardiac autoantibodies have been detected in DCM patients. Circulating antibodies are extractable by immunoadsorption (IA). Recent open controlled pilot studies have shown that removal of circulating antibodies by IA induces improvement of cardiac function in DCM. IA, furthermore, decreases myocardial inflammation. In vitro data indicate that removal of negative inotropic antibodies may represent the essential mechanism of IA in DCM. These antibodies belong to immunoglobulin G subclass 3 and may play an important role in cardiac dysfunction of DCM patients. Recent data indicate that the Fc fragments of the immunoglobulins that bind to newly detected sarcolemma-specific Fcg receptors IIa are involved in the functional effects of cardiac autoantibodies. Removal of various cardiac antibodies through unspecific IA could therefore offer a hopeful treatment approach in DCM for intervention into this autoimmune process.


Leave Ventricular Ejection Fraction Dilate Cardiomyopathy Negative Inotropic Effect Humoral Immune System Cardiac Myosin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB (2006) Contemporary definitions and classification of the cardiomyopathies: An American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 113: 1807–1816CrossRefPubMedGoogle Scholar
  2. 2.
    Dec GW, Palacios IF, Fallon JT, Aretz HT, Mills J, Lee DC, Johnson RA (1985) Active myocarditis in the spectrum of acute dilated cardiomyopathies. Clinical features, histologic correlates, and clinical outcome. N Engl J Med 312: 885–890CrossRefPubMedGoogle Scholar
  3. 3.
    Feldman AM, McNamara DM (2000) Myocarditis. N Engl J Med 343: 1388–1398CrossRefPubMedGoogle Scholar
  4. 4.
    Kühl U, Pauschinger M, Noutsias M, Seeberg B, Bock T, Lassner D, Poller W, Kandolf R, Schultheiss HP (2005) High prevalence of viral genomes and multiple viral infections in the myocardium of adults with “idiopathic” left ventricular dysfunction. Circulation 111: 887–893CrossRefPubMedGoogle Scholar
  5. 5.
    Bowles NE, Richardson PJ, Olsen EG, Archard LC (1986) Detection of coxsackie-Bvirus-specific RNA sequences in myocardial biopsy samples from patients with myocarditis and dilated cardiomyopathy. Lancet 1: 1120–1123CrossRefPubMedGoogle Scholar
  6. 6.
    Kandolf R, Ameis D, Kirschner P, Canu A, Hofschneider PH (1987) In situ detection of enteroviral genomes in myocardial cells by nucleic acid hybridization: An approach to the diagnosis of viral heart disease. Proc Natl Acad Sci USA 84: 6272–6276CrossRefPubMedGoogle Scholar
  7. 7.
    Pauschinger M, Bowles NE, Fuentes-Garcia FJ, Pham V, Kühl U, Schwimmbeck PL, Schultheiss HP, Towbin JA (1999) Detection of adenoviral genome in the myocardium of adult patients with idiopathic left ventricular dysfunction. Circulation 99: 1348–1354PubMedGoogle Scholar
  8. 8.
    Liu PP, Mason JW (2001) Advances in the understanding of myocarditis. Circulation 104: 1076–1082CrossRefPubMedGoogle Scholar
  9. 9.
    Magnani JW, Dec GW (2006) Myocarditis: Current trends in diagnosis and treatment. Circulation 113: 876–890CrossRefPubMedGoogle Scholar
  10. 10.
    Kühl U, Pauschinger M, Seeberg B, Lassner D, Noutsias M, Poller W, Schultheiss HP (2005) Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 112: 1965–1970CrossRefPubMedGoogle Scholar
  11. 11.
    Kühl U, Noutsias M, Schultheiss HP (1995) Immunohistochemistry in dilated cardiomyopathy. Eur Heart J 16 Suppl O: 100–106PubMedGoogle Scholar
  12. 12.
    Wojnicz R, Nowalany-Kozielska E, Wodniecki J, Szczurek-Katanski K, Nozynski J, Zembala M, Rozek MM (1998) Immunohistological diagnosis of myocarditis. Potential role of sarcolemmal induction of the MHC and ICAM-1 in the detection of autoimmune mediated myocyte injury. Eur Heart J 19: 1564–1572CrossRefPubMedGoogle Scholar
  13. 13.
    Noutsias M, Seeberg B, Schultheiss HP, Kühl U (1999) Expression of cell adhesion molecules in dilated cardiomyopathy: Evidence for endothelial activation in inflammatory cardiomyopathy. Circulation 99: 2124–2131PubMedGoogle Scholar
  14. 14.
    Schultheiss HP, Kühl U, Janda I, Melzner B, Ulrich G, Morad M (1988) Antibodymediated enhancement of calcium permeability in cardiac myocytes. J Exp Med 168: 2102–2119CrossRefGoogle Scholar
  15. 15.
    Caforio AL, Grazzini M, Mann JM, Keeling PJ, Bottazzo GF, McKenna WJ, Schiaffino S (1992) Identification of alpha-and beta-cardiac myosin heavy chain isoforms as major autoantigens in dilated cardiomyopathy. Circulation 85: 1734–1742PubMedGoogle Scholar
  16. 16.
    Wallukat G, Wollenberger A, Morwinski R, Pitschner HF (1995) Anti-beta1-adrenoceptor autoantibodies with chronotropic activity from the serum of patients with dilated cardiomyopathy: Mapping of epitopes in the first and second extracellular loops. J Mol Cell Cardiol 27: 397–406CrossRefPubMedGoogle Scholar
  17. 17.
    Fu LX, Magnusson Y, Bergh CH, Liljeqvist JA, Waagstein F, Hjalmarson A, Hoebeke J (1993) Localization of a functional autoimmune epitope on the muscarinic acetylcholine receptor-2 in patients with idiopathic dilated cardiomyopathy. J Clin Invest 91: 1964–1968CrossRefPubMedGoogle Scholar
  18. 18.
    Baba A, Yoshikawa T, Ogawa S (2002) Autoantibodies produced against sarcolemmal Na-K-ATPase: Possible upstream targets of arrhythmias and sudden death in patients with dilated cardiomyopathy. J Am Coll Cardiol 40: 1153–1159CrossRefPubMedGoogle Scholar
  19. 19.
    Lauer B, Schannwell M, Kühl U, Strauer BE, Schultheiss HP (2000) Antimyosin autoantibodies are associated with deterioration of systolic and diastolic left ventricular function in patients with chronic myocarditis. J Am Coll Cardiol 35: 1106–1110CrossRefGoogle Scholar
  20. 20.
    Felix SB, Staudt A., Landsberger M, Grosse Y, Stangl V, Spielhagen T, Wallukat, G, Wernecke K-D, Baumann G, Stangl K (2002) Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption. J Am Coll Cardiol 39: 646–652CrossRefPubMedGoogle Scholar
  21. 21.
    Li Y, Heuser JS, Cunningham LC, Kosanke SD, Cunningham MW (2006) Mimicry and antibody-mediated cell signaling in autoimmune myocarditis. J Immunol 177: 8234–8240PubMedGoogle Scholar
  22. 22.
    Fu ML, Schulze W, Wallukat G, Hjalmarson A, Hoebeke J (1996) A synthetic peptide corresponding to the second extracellular loop of the human M2 acetylcholine receptor induces pharmacological and morphological changes in cardiomyocytes by active immunization after 6 months in rabbits. Clin Immunol Immunopathol 78: 203–207CrossRefPubMedGoogle Scholar
  23. 23.
    Matsui S, Fu ML, Katsuda S, Hayase M, Yamaguchi N, Teraoka K, Kurihara T, Takekoshi N, Murakami E, Hoebeke J, Hjalmarson A (1997) Peptides derived from cardiovascular G-protein-coupled receptors induce morphological cardiomyopathic changes in immunized rabbits. J Mol Cell Cardiol 29: 641–655CrossRefPubMedGoogle Scholar
  24. 24.
    Jahns R, Boivin V, Hein L, Triebel S, Angermann CE, Ertl G, Lohse MJ (2004) Direct evidence for a beta1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest 113: 1419–1429PubMedGoogle Scholar
  25. 25.
    Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, Sasayama S, Mizoguchi A, Hiai H, Minato N, Honjo T (2001) Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291: 319–322CrossRefPubMedGoogle Scholar
  26. 26.
    Okazaki T, Tanaka Y, Nishio R, Mitsuiye T, Mizoguchi A, Wang J, Ishida M, Hiai H, Matsumori A, Minato N, Honjo T (2003) Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 9: 1477–1483CrossRefPubMedGoogle Scholar
  27. 27.
    Bygren P, Freiburghaus C, Lindholm T, Simonsen O, Thysell H, Wieslander J (1985) Goodpasture’s syndrome treated with staphylococcal protein A immunoadsorption. Lancet 2: 1295–1296CrossRefPubMedGoogle Scholar
  28. 28.
    Palmer A, Gjorstrup P, Severn A, Welsh K, Taube D (1988) Treatment of systemic lupus erythematodes by extracorporeal immunoadsorption. Lancet 2: 272CrossRefPubMedGoogle Scholar
  29. 29.
    Dörffel WV, Felix SB, Wallukat G, Brehme S, Bestvater K, Hofmann T, Kleber FX, Baumann G (1997) Short-term hemodynamic effects of immunoadsorption in dilated cardiomyopathy. Circulation 95: 1994–1997PubMedGoogle Scholar
  30. 30.
    Felix SB, Staudt A, Dörffel WV, Stangl V, Merkel K, Pohl M, Döcke WD, Morgera S, Neumayer HH, Wernecke KD, Wallukat G, Stangl K, Baumann G (2000) Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: Three-month results from a randomized study. J Am Coll Cardiol 35: 1590–1598CrossRefPubMedGoogle Scholar
  31. 31.
    Müller J, Wallukat G, Dandel M, Bieda H, Brandes K, Spiegelsberger S, Nissen E, Kunze R, Hetzer R (2000) Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation 101: 385–391PubMedGoogle Scholar
  32. 32.
    Staudt A, Schaper F, Stangl V, Plagemann A, Böhm M, Merkel K, Wallukat G, Wernecke K-D, Stangl K, Baumann G, Felix SB (2001) Immunohistological changes in dilated cardiomyopathy induced by immunoadsorption therapy and subsequent immunoglobulin substitution. Circulation 103: 2681–2686PubMedGoogle Scholar
  33. 33.
    Matsui S, Larsson L, Hayase M, Katsuda S, Teraoka K, Kurihara T, Murano H, Nishikawa K, Fu M (2006) Specific removal of beta1-adrenoceptor autoantibodies by immunoabsorption in rabbits with autoimmune cardiomyopathy improved cardiac structure and function. J Mol Cell Cardiol 41: 78–85CrossRefPubMedGoogle Scholar
  34. 34.
    Mobini R, Staudt A, Felix SB, Baumann G, Wallukat G, Deinum J, Svensson H, Hjalmarson A, Fu M (2003) Hemodynamic improvement and removal of autoantibodies against beta1-adrenergic receptor by immunoadsorption therapy in dilated cardiomyopathy. J Autoimmun 20: 345–350CrossRefPubMedGoogle Scholar
  35. 35.
    Horn S, Lueking A, Murphy D, Staudt A, Gutjahr C, Schulte K, König A, Landsberger M, Lehrach H, Felix SB, Cahill DJ (2006) Profiling humoral auto-immune repertoire of dilated cardiomyopathy (DCM) patients and development of a disease-associated protein chip. Proteomics 6: 605–613CrossRefPubMedGoogle Scholar
  36. 36.
    Chen J, Larsson L, Haugen E, Fedorkova O, Angwald E, Waagstein F, Fu M (2006) Effects of autoantibodies removed by immunoadsorption from patients with dilated cardiomyopathy on neonatal rat cardiomyocytes. Eur J Heart Fail 8: 460–467CrossRefPubMedGoogle Scholar
  37. 37.
    Staudt A, Staudt Y, Dörr M, Böhm M, Knebel F, Hummel A, Wunderle L, Tiburcy M, Wernecke K-D, Baumann G, Felix SB (2004) Potential role of humoral immunity in cardiac dysfunction of patients suffering from dilated cardiomyopathy. J Am Coll Cardiol 44: 829–836CrossRefPubMedGoogle Scholar
  38. 38.
    Bruggemann M, Williams GT, Bindon CI, Clark MR, Walker MR, Jefferis R, Waldmann H, Neuberger MS (1987) Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med 166: 1351–1361CrossRefPubMedGoogle Scholar
  39. 39.
    Warraich RS, Noutsias M, Kazak I, Seeberg B, Dunn MJ, Schultheiss HP, Yacoub MH, Kühl U, Kasac I (2002) Immunoglobulin G3 cardiac myosin autoantibodies correlate with left ventricular dysfunction in patients with dilated cardiomyopathy: Immunoglobulin G3 and clinical correlates. Am Heart J 143: 1076–1084CrossRefPubMedGoogle Scholar
  40. 40.
    Staudt A, Böhm M, Knebel F, Grosse Y, Bischoff C, Hummel A, Dahm JB, Borges A, Jochmann N, Wernecke K-D, Wallukat G, Baumann G, Felix SB (2002) Potential role of autoantibodies belonging to the immunoglobulin G-3 subclass in cardiac dysfunction among patients with dilated cardiomyopathy. Circulation 106: 2448–2453CrossRefPubMedGoogle Scholar
  41. 41.
    Staudt A, Dörr M, Staudt Y, Böhm M, Probst M, Empen K, Plötz S, Maschke HE, Hummel A, Baumann G, Felix SB (2005) Role of immunoglobulin G3 subclass in dilated cardiomyopathy Results from protein-A immunoadsorption. Am Heart J 150: 729–36CrossRefPubMedGoogle Scholar
  42. 42.
    Staudt A, Eichler P, Trimpert C, Felix SB, Greinacher A (2007) Fc(gamma) receptors IIa on cardiomyocytes and their potential functional relevance in dilated cardiomyopathy. J Am Coll Cardiol 49: 1684–92CrossRefPubMedGoogle Scholar

Copyright information

© Springer Basel 2010

Authors and Affiliations

  • Stephan B. Felix
    • 1
  • Alexander Staudt
    • 1
  1. 1.Klinik für Innere Medizin BErnst-Moritz-Arndt-UniversitätGreifswaldGermany

Personalised recommendations